New Guidelines Lower Cholesterol Treatment Thresholds, Emphasize Early Intervention

Major changes in cardiovascular disease prevention were recommended on Friday, suggesting individuals as young as 30 – down from age 40 – should consider statins or other measures to manage cholesterol. The updated recommendations move beyond focusing solely on LDL (“bad”) cholesterol and statins, adopting a broader approach to preventing and treating cardiovascular diseases caused by the hardening and narrowing of arteries.

Earlier Intervention for Lowering Risk

Behavioral changes or medication are now encouraged when LDL cholesterol reaches 160 mg/dL or higher in individuals without heart disease, starting in young adulthood at age 30. This approach begins with healthier lifestyle habits, with the potential to add statins or other drugs if there’s a strong family history of early heart disease or a risk assessment indicates a heightened 30-year risk of developing cardiovascular disease. If diet and exercise aren’t sufficient to lower lipid levels, imaging to assess calcium in coronary arteries can be considered to evaluate some individuals’ risk of heart attack or stroke before initiating medication.

“These guidelines represent an critical shift toward identifying higher-risk individuals earlier and treating them more effectively,” said Gregg Fonarow, a cardiologist and professor of cardiovascular medicine and science at UCLA via email. He was not involved in drafting the guidelines. “It is deeply concerning that so many cardiovascular events occur each year that could have been prevented with earlier identification and treatment of risk. These new guidelines provide a clearer, more contemporary roadmap that can help reduce this burden.”

New Guidelines Based on Updated Risk Calculator

The new guidelines from the American College of Cardiology, the American Heart Association, and nine other medical organizations are based on a risk calculator released in November 2024, which has been hailed as more reliable than previous equations.

The new PREVENT equations (short for Predicting Risk of Cardiovascular Disease EVENTs) are embraced in the 2026 guidelines, along with adjustments to the threshold for taking action to clear arteries of fatty plaque. The optimal level of LDL is lower, and the risk threshold for prescribing better diet and physical activity, drugs, or both has also been adjusted downward.

Timothy Anderson, a primary care physician and assistant professor of medicine at the University of Pittsburgh Medical Center, and a member of the 2026 guidelines writing committee, praised the PREVENT equations as a well-validated risk estimation tool with updated accuracy.

“The full rationale is really this idea of trying to balance the potential benefit of lipid-lowering therapies like statins against the potential risks,” he said. “A real focus of the guidelines is identifying and treating high cholesterol earlier on, out of the hypothesis that long-term exposure to high cholesterol may have greater risks than short-term exposure.”

Understanding Risk Categories

Earlier recognition involves looking at both 10-year and 30-year risk estimates. The new PREVENT equations classify 10-year cardiovascular disease risk as:

• Low (under 3%)
• Borderline (3% to 5%)
• Intermediate (5% to 10%)
• High (10% or higher)

These risk categories form the foundation for treatment decisions, ranging from initiating statin therapy to determining the intensity of lipid lowering. Factors such as family history, inflammatory disease, diabetes, kidney disease, cancer, HIV, and certain reproductive conditions influence risk calculation.

Lower LDL Targets Based on Risk

Treatment is now recommended at much lower LDL levels, depending on an individual’s current health. To prevent a first heart attack or stroke:

• LDL should be under 100 mg/dL for those at borderline or intermediate risk.
• LDL should be under 70 mg/dL for those at high risk.
• For individuals with existing fatty buildup in blood vessels at very high risk of heart attack, stroke, or peripheral artery disease, the LDL goal drops to under 55 mg/dL.

Beyond Statins: A Multifaceted Approach

Roger Blumenthal, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, compared lipid-lowering drugs to medications to reduce blood pressure. The longer both are controlled, the better the protection against future heart attack and stroke risk.

“The PREVENT score gives us a good educated guess, but keep in mind these numbers are pretty low when we talk about intermediate risk being a 5% to 10% 10-year risk,” he said. “Some patients have already said, ‘Well, Dr. Blumenthal, that’s a 1 in 20 chance that I’ll get a cardiovascular event.’ That’s very true. But I tell them that if you have other factors that support earlier treatment, that may sway us to being more aggressive in your management.”

Other Factors Influencing Risk

Beyond family history, risk enhancers include being overweight or obese, diabetes, chronic kidney disease, and chronic inflammatory conditions such as lupus or rheumatoid arthritis. South Asian or Filipino ancestry also increases the risk of developing atherosclerosis.

Women typically develop atherosclerotic disease about 10 years later than men, but this delay is erased if they experience early premature menopause, preeclampsia, gestational diabetes, or hypertension during pregnancy.

The Role of Additional Biomarkers

Markers beyond cholesterol, such as Lipoprotein(a), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein, are gaining attention in assessing risk. Lp(a), affecting about 1 in 5 people worldwide, should be measured once in a lifetime; levels 50 mg/dL or higher are associated with a 40% increased long-term risk of heart attack or stroke. Lifestyle changes don’t alter Lp(a) levels, but high Lp(a) combined with high LDL should prompt a discussion about lowering LDL.

In people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have reached their cholesterol goals, ApoB may be a more accurate risk marker than LDL cholesterol.

Statins Remain a Cornerstone of Prevention

Throughout the guidelines, the emphasis isn’t solely on statins or LDL cholesterol. Recognizing that not everyone who could benefit takes statins, the authors still acknowledge their place in early treatment. Statins, introduced in the 1980s, have had a significant impact in preventing heart attacks, strokes, and peripheral artery disease and are available at a low annual cost of around $40.

While side effects like muscle pain and a slight increase in blood sugar are possible, Blumenthal said 95% or more patients experience no difficulties with the drug.

Other drugs for cholesterol control, such as PCSK9 inhibitors, are available for cases where lipids remain high, but they are significantly more expensive.

Coronary artery calcium scans can also help with treatment decisions when risk is uncertain, revealing calcium and plaque buildup in artery walls. These scans are recommended for men age 40 and up and women age 45 and up who are at borderline or intermediate risk.

“The hardest thing really is to motivate people to improve their lifestyle habits,” Blumenthal said. “But it’s also hard many times to get people to understand that we have such a multitude of great data about lower is better for longer. If we can motivate people to keep striving to improve their lifestyle habits earlier, then there’d be less of a need for medication and less of the need for dealing with all these acute cardiac events that unfortunately plague so many people in the United States and worldwide.”